Richard G. Harris, MD, led a panel discussion on “Managing Prostate Cancer Patients and LHRH Injection Times During COVID-19” for the Grand Rounds in Urology audience in June, 2020.
How to cite: Harris, Richard G. Langford, Timothy D. Saltzstein, Daniel R. Crawford, E. David. “Managing Prostate Cancer Patients and LHRH Injection Times During COVID-19” June, 2020. Accessed Dec 2024. https://dev.grandroundsinurology.com/managing-prostate-cancer-patients-and-lhrh-injection-times-during-covid-19/
Managing Prostate Cancer Patients and LHRH Injection Times During COVID-19 – Summary:
Richard Harris, MD, President of LUGPA and CEO of UroPartners, moderates a discussion between Daniel R. Saltzstein, MD, from Urology San Antonio, and Timothy D. Langford, MD, from Arkansas Urology. They discuss the challenges of managing prostate cancer patients during COVID-19, including the ways the pandemic has changed the manner and frequency of how they bring in patients in for treatment, particularly for therapies like androgen deprivation. Both Dr. Saltzstein and Dr. Langford emphasize the precautions they are taking at their practices to address the risks of COVID-19, and acknowledge how challenging this patient population can be given their need for frequent visits. They highlight the limitations of telehealth, as well as the risks of not bringing patients in often enough to receive the therapies that they need, even though lengthening the time between visits has been the answer a lot of doctors have found to reduce the risk of COVID-19 exposure.
To expand your knowledge of androgen deprivation therapy, visit our ADT Next Generation Learning Center.
ABOUT THE AUTHOR
Richard Harris, MD, is a board-certified urologist with expertise in the treatment of advanced prostate cancer and health policy. He obtained his BA cum laude from Washington University in St. Louis, Missouri. He then completed a year of graduate work in biological science at the University of Illinois in Chicago, followed by medical school at the Chicago Medical School at Rosalind Franklin University. He completed residency training in general surgery and urology at Loyola University Medical Center in Chicago. Dr. Harris has been involved in clinical drug development and research on over 70 drug trials and has also been on the advisory board for several pharmaceutical companies. Currently, he sits on the Board of Directors of LUGPA and is LUGPA’s President. He is a founding member, CEO, and President of UroPartners, LLC, the largest group of urologists in the Midwest.
Dr. Harris is an Assistant Clinical Professor of Urology at the Loyola University Medical Center. His area of interest is urology and his specialty is advanced prostate cancer. Dr. Harris is also interested in BPH, sexual dysfunction, and kidney stone disease. Dr. Harris is one of the few urologists skilled in cryotherapy for prostate cancer.
